Medical Device Preclinical Bootcamp
|
|
- Ferdinand Evans
- 6 years ago
- Views:
Transcription
1 Medical Device Preclinical Bootcamp March 30, :30am - 2:30pm Massachusetts Biotechnology Council (MassBio) 300 Technology Square, 8th Floor Cambridge, MA Featured Speakers Rosalyn Año Laurence Lister Stephen Doherty, Ph.D. Kevin Connor, Ph.D., DABT Russell Sloboda Bootcamp Coverage The Basics of Biocompatibility Testing Chemical Characterization of Medical Devices: Strategies, Pitfalls, and Points of Consideration Toxicological Risk Assessment Based on Extractable/Leachable Data: Why, When, and How Toxicological Risk Assessment for Breathing Gas Pathway Medical Devices: ISO and ISO Tips for a Successful Sponsor-Laboratory Partnership
2 Medical Device Preclinical Bootcamp 9:30 10:00: Registration 10:00 10:15: Welcome and Introduction: The Medical Device Approval Pathway 10:15 11:45: The Basics of Biocompatibility Testing The Basics of Biocompatibility Testing Biocompatibility simply refers to the properties of materials being biologically compatible by not eliciting local or systemic responses from a living system or tissue. This presentation will discuss the basics of biocompatibility testing. This presentation will discuss the history and evaluation of biocompatibility. It will explain how to properly classify your device. Then when biological endpoints are applicable for the properly labeled device will be covered. Finally, a high level discussion of each biological evaluation and the various choices will be explained. 11:45 12:15: Lunch and Networking 12:15 1:00: Chemical Characterization of Medical Devices: Strategies, Pitfalls, and Points of Consideration Recent regulatory guidance documents have emphasized the need for chemical characterization of medical devices as part of an overall device assessment. We will examine the types of information available from a chemical characterization and how to get the information you are looking for from the testing. Strategies for study design and execution will be discussed. Common pitfalls and potential shortcomings and how to avoid them will also be presented. 1:00 2:00: Toxicological Risk Assessment Based on Extractable/Leachable Data: Why, When, and How Toxicological Risk Assessment (TRA) has been an important tool in the safety assessment of biomedical devices, providing a chemical-based approach which complements a more traditional testing program largely based on whole animal studies. The need for TRA is growing and in some cases, will be considered as a means of circumventing animal testing in the safety evaluation of devices. TRA is founded on the notion that, if all constituents of a product, including additive, impurities and contaminants, are known, then the safety (or risk) of a product can be assessed based on the toxicology of those constituents, ascertained through extractable / leachable (E/L) studies. However, the E/L analysis can face several pitfalls towards achieving the objectives of risk assessment and current regulatory guidance leaves the analyst having to make many choices based on their own judgment. However, this shortcoming of the data can be avoided with proper study design. Potential pitfalls in the E/L analysis will be discussed together some tested methods for their avoidance, which will be illustrated with case studies. 2:00 2:20: Toxicological Risk Assessment for Breathing Gas Pathway Medical Devices: ISO and ISO 1856 Breathing gas pathway medical devices such as breathing systems, ventilators, anesthesia systems, nebulizers and oxygen lines come into contact with patients at a particularly vulnerable point and time. Bootcamp Agenda
3 Bootcamp Agenda Medical Device Preclinical Bootcamp As a result, the exposure assessment for these devices is an important step in the evaluation of device safety and needs to be particularly concerned with airborne releases, especially volatile organic compound (VOCs). ISO and ISO may both apply; yet in some instances each standard recommends a very different technical approach to the measurement of releasable chemicals and different assumptions for the risk assessment. The key differences in these two methodologies will be illustrated, along with an analysis of how different risk estimates derived using these regulatory guidelines points out the need to justify the use of one over the other. 2:20 2:35: Tips for a Successful Sponsor-Laboratory Partnership With over 40 years of experience and having completed thousands of studies, Toxikon has seen the good, the bad, and the ugly of medical device safety and efficacy testing. With our customers, collectively we ve learned how proper preparation, comprehensive communication, and clear expectations on both sides creates an environment where studies are initiated efficiently and completed effectively. We will facilitate an open discussion sharing what we ve learned about creating a successful partnership between the sponsoring company and the contract laboratory, to help your next project have the best chance for success.
4 Medical Device Preclinical Bootcamp Rosalyn Año Business Development Manager Stephen Doherty, Ph.D. Director of Analytical Chemistry Workshop Faculty Rosalyn has more than 10 years of experience in guiding medical device companies through successful product safety testing strategies. As one of Toxikon s business development managers, she has a track record of controlling study costs through sound risk management techniques, reducing the probability of test failure, and streamlining product development timelines to achieve key milestones ultimately resulting in a high success rate of getting high quality and safe products to market. Rosalyn received her B.S. in Biomedical Engineering from Boston University. Laurence Lister Director of Biocompatibility Laurence has over 25 years of experience in every aspect of biocompatibility and toxicology testing. As Toxikon s head of biocompatibility, he is responsible for the direction of the staff of scientists that perform thousands of biocompatibility studies each year. Laurence has authored several papers on the specifics of biocompatibility tests, and is a member of several national and international committees that steer biocompatibility regulation and guidance. Laurence received his B.S. in Biology from Boston College. Stephen has more than 20 years of experience in chemical testing and characterization of medical devices and related products. As Toxikon s director of analytical chemistry, he develops experimental study designs to address client-specific test and regulatory requirements. Dr. Doherty is the author of a number of articles and book chapters on polymer formulation, testing, and applications, and is a frequent presenter on extractable / leachable topics at industry conferences around the country each year. Stephen received his B.A. in Chemistry from Colby College and a Ph.D. in Analytical Chemistry from the University of New Hampshire.
5 Workshop Faculty Medical Device Preclinical Bootcamp Kevin Connor, Ph.D., DABT Director of ToxSMART Consulting Practice Kevin has more than 20 years of experience in toxicology and human health risk assessment within a variety of regulatory frameworks. As head of Toxikon s risk assessment consulting division, ToxSMART, he has managed hundreds of risk assessments for medical devices and consumer products, including assessments under ISO Dr. Connor works closely with Toxikon s analytical laboratories in procuring the most relevant data from extractability leachability (E/L) analyses to best help sponsors develop methods that carefully consider the nature of consumer exposure. Russell Sloboda Study Director ToxSMART Consulting Practice Russell Sloboda is an analytical chemist and risk assessment specialist with 35 years experience. At Toxikon he is responsible for all aspects of toxicological risk assessment as per ISO and ICH M7 guidelines, which includes literature research, exposure modeling, investigation of medical device and drug product manufacturing practice and usage, application of QSAR models to screen chemical toxicity, development of toxicological profiles, and calculation of tolerable intakes based on extrapolation of animal toxicity data. He communicates effectively and provides consulting support in analytical study design, specification of AETs, and response to FDA comments.
6 Medical Device Preclinical Bootcamp Registration Information: Online: Venue Information: Massachusetts Biotechnology Council (MassBio) 300 Technology Square, 8th Floor Cambridge, MA Directions / Parking: Accessible via the MBTA at the Kendall Square stop, Red Line. Parking available at Technology Square Garage, 595 Technology Square, Cambridge, MA Registration
Biocompatibility Testing for Medical Devices
Biocompatibility Testing for Medical Devices *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! The medical device field is one of the most heavily regulated industries, for obvious
More informationBiocompatibility Testing for Medical Devices
Biocompatibility Testing for Medical Devices *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! The medical device field is one of the most heavily regulated industries, for obvious
More informationNAMSA is a Medical Research Organization (MRO), accelerating product development
NAMSA is a Medical Research Organization (MRO), accelerating product development through integrated laboratory, clinical and consulting services. Driven by our regulatory expertise, NAMSA's MRO Approach
More informationSafety Qualification Process and Application of Thresholds. Jim Blanchard PQRI L&E Toxicology Subgroup Principal Scientist Aradigm
Safety Qualification Process and Application of Thresholds Jim Blanchard PQRI L&E Toxicology Subgroup Principal Scientist Aradigm Outline Safety qualification process What to do when leachables exceed:
More informationISO Series Biocompatibility evaluation of breathing gas pathways in healthcare applications
ISO 18562 Series Biocompatibility evaluation of breathing gas pathways in healthcare applications James Morrison LIVE WEBINAR November 2018 2018 Brandwood Biomedical www.brandwoodbiomedical.com James (Morrison)
More informationAddressing challenges in Drug Development and Quality Control with innovative solutions
Addressing challenges in Drug Development and Quality Control with innovative solutions SYNOPSIS 16 May 2013, 9:30 am 3:00 pm Gd. Titan Centre (Theater Room) This seminar is designed for scientists in
More informationBIOCOMPATIBILITY TESTING OF GAS PATHWAYS IN MEDICAL DEVICES
BIOCOMPATIBILITY TESTING OF GAS PATHWAYS IN MEDICAL DEVICES EXECUTIVE SUMMARY Many medical devices used to assist in the diagnosis, monitoring or treatment of respiratory issues or to deliver anesthesia
More informationColorants in Medical Devices:
Colorants in Medical Devices: The Spectrum of Current Regulatory Expectations John Iannone Program Manager/ Technical Specialist Overview» Company Introduction» Why use Colorants in Devices?» Regulatory
More informationDesign Perspectives on. Drug/Biologic Delivery. Medtronic Neuromodulation. Luis Fesser Deanna Lane Jeanmarie Sales July 16, 2012
Design Perspectives on Implantable Devices for Targeted Drug/Biologic Delivery Medtronic Neuromodulation Steve Christenson Luis Fesser Deanna Lane Jeanmarie Sales July 16, 2012 The following presentation
More informationSatisfying ISO and US FDA Biocompatibility requirements for Breathing Gas Pathways in Healthcare Application
Satisfying ISO 18562 and US FDA Biocompatibility requirements for Breathing Gas Pathways in Healthcare Application Audrey Turley, B.S., RM (NRCM), CBA Biocompatibility Expert 801-290-7907 aturley@nelsonlabs.com
More informationIntroduction to clinical trials Magnus Kjaer
Introduction to clinical trials 2016-01-20 Magnus Kjaer One Definition of Clinical Trial NIH 2014 A research study in which one or more human subjects are prospectively assigned to one or more interventions
More informationDerivation and Justification of Safety Thresholds
Derivation and Justification of Safety Thresholds Douglas J. Ball, MS, DABT Chair, PQRI L&E Toxicology Subgroup Research Fellow, Safety Sciences - Pfizer, Inc. Agenda Basic Definitions Current Regulatory
More informationIntroduction to clinical trials
Introduction to clinical trials Definition of a clinical trial A research activity that involves administration of a test treatment to some experimental unit in order to evaluate the treatment. Key words
More informationFrom Bench to Bedside. Russ H. Read June 23, 2014
From Bench to Bedside Russ H. Read June 23, 2014 Talent Required Scientists, clinicians, technicians, chemists, biologists, pharmacologists, toxicologists, research associates, regulatory experts, manufacturing
More informationConducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development
Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development 2015 AAPS Annual Meeting and Exposition October 28, 2015 Kimberly Raines, Ph.D. Lead Pharmacologist Quality
More informationFUTURE MEANS CREATIVITY
START-UP & ACADEMICS THEORY & PRACTICE IN DRUG DEVELOPMENT 1 EARLY PHASE DRUG DEVELOPMENT COURSE MAY 9 TH 2017 - ANTWERP FUTURE MEANS CREATIVITY VENUE: LINDNER HOTEL LANGE KIEVITSTRAAT 125 BE-2018 ANTWERP,
More informationExtractables and Leachables in Early Phase Development
Extractables and Leachables in Early Phase Development Wayland Rushing, Ph.D. Senior Scientific Advisor, ABC 11/23/2015 Product and Process Variants & Impurities 1 Regulatory Perspective Dr. Ingrid Markovic,
More informationExtractables & Leachables Boston 2019 Ensuring Quality, Safety, Suitability and Regulatory Compliance for Drugs, Biologics and Medical Devices
Ensuring Quality, Safety, Suitability and Regulatory Compliance for Drugs, Biologics and Medical Devices April 10 11, 2019, Metro Meeting Centers, Boston, MA Featuring Lessons Learned and Case Studies
More informationExtractables and leachables: An Introduction
Extractables and leachables: An Introduction Tim Hulme Smithers Rapra THulme@smithers.com 44(0)1939 252 418 1 Extractables and leachables: An Introduction Tim Hulme Smithers Rapra thulme@smithers.com 2
More informationDrug Impurities: The Good, Bad and Ugly
Drug Impurities: The Good, Bad and Ugly Joel Bercu, PhD, DABT, MPH Associate Director, Environmental and Occupational Toxicology Gilead Sciences jbercu@gilead.com Medicines Impurities 2015-2016 GrimsrudBerkowitz
More informationValidation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH)
Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH) *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY!
More informationHow to Prepare MedDevice Packaging for Regulatory Success A Chemical Characterization (E&L) Perspective
How to Prepare MedDevice Packaging for Regulatory Success A Chemical Characterization (E&L) Perspective Frank Bieganousky, AMRI Wei Zhang, Ph.D., AMRI Purpose» Demonstrate a proactive approach for integration
More informationINVESTIGATIONS BOOTCAMP NIBRT (NATIONAL INSTITUTE FOR BIO-PROCESSING RESEARCH AND TRAINING)
INVESTIGATIONS BOOTCAMP IN PARTNERSHIP WITH NIBRT (NATIONAL INSTITUTE FOR BIO-PROCESSING RESEARCH AND TRAINING) Dates: January 29 th - 31 st, 2013 Time: 8:30am-5:30pm Venue: NIBRT, Dublin Training Outline
More informationLeachables and Extractables Outlook PODP Accomplishments and Next Steps
Leachables and Extractables Outlook PODP Accomplishments and Next Steps Diane M. Paskiet Associate Director of Scientific Affairs West PQRI PODP Workshop February 22-23, 2011 Improvement A Priori Reasoning
More informationBRIEFING. . Over time, 466 may be used less frequently and may be withdrawn.
Page 1 of 13 BRIEFING 1086 USP 37 page 828. As part of an ongoing monograph modernization initiative, the United States Pharmacopeial Convention (USP) is updating this general chapter, 1086 Impurities
More informationIMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Recommended for
More informationPharmaceutical Toxicology: Toxicology in the Nonclinical Development of Drugs and Biologics. December 3-4, 2012 PERI Training Facility ~ Arlington, VA
Pharmceutical Toxicology: Tentative Agenda Pharmaceutical Toxicology: Toxicology in the Nonclinical Development of Drugs and Biologics December 3-4, 2012 PERI Training Facility ~ Arlington, VA Monday,
More informationThursday, April 17, :30 pm to 9:00 pm UMass Lowell Emerging Technologies and Innovation Center 40 University Avenue Lowell, Massachusetts
Want to participate in the UMass Dartmouth program but the UMD campus is too far away? Have we got a great idea for you! Join the Boston Area Chapter on April 17 th at U Mass Lowell and be part of several
More informationIntegrating Toxicological Information Effectively Throughout Organizations. Joel Bercu PhD MPH DABT Director, Gilead Sciences
Integrating Toxicological Information Effectively Throughout Organizations Joel Bercu PhD MPH DABT Director, Gilead Sciences Environmental and Occupational Toxicology Mission Protect patients, employees,
More informationRegulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA
Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is
More informationCTA/NDA Regulatory Landscape in China. Jack Xie, PhD, DABT SOT 2016
CTA/NDA Regulatory Landscape in China Jack Xie, PhD, DABT SOT 2016 Disclaimer The content of the following presentation represents solely author s view and may not reflect any position of Roche or China
More informationExtractable and Leachable Studies of Parenteral Infusion and Transfusion Products
Extractable and Leachable Studies of Parenteral Infusion and Transfusion Products Jianfeng Hong Fresenius Kabi USA LLC. 3 Corporate Drive, Lake Zurich, Illinois 60047, USA Overview Fresenius Kabi and Products.
More informationModern Approaches to Process Understanding
Biomanufacturing and Process Development (BPD) Modern Approaches to Process Understanding Thursday, September 18, 2014 1:00 pm - Registration begins 1:15 5:00 pm - Presentations & Networking North Carolina
More informationImpurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA
Overview of exploratory INDs Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA July, 15 16, 2008 David Jacobson-Kram, Ph.D. DABT Office of New Drugs Center for Drug Evaluation
More informationontainer Closure Systems
C PharmaED s Register by July 1 st and receive a $300 Discount! ontainer Closure Systems Strategies for Selection, Compliance and Mitigation of Extractables and Leachables Challenges SEPTEMBER 15-16, 2008,
More informationScientific and Regulatory Perspectives on Measuring Protein Aggregation of Biotechnology Products
Scientific and Regulatory Perspectives on Measuring Protein Aggregation of Biotechnology Products Ashutosh Rao, Ph.D. Chief, Laboratory of Applied Biochemistry Division of Biotechnology Review and Research
More informationMethod Validation Studies How GLP Interacts With Guidance Documents
Method Validation Studies How GLP Interacts With Guidance Documents Steven S. Kuwahara ROBERT GEORGE YOUNG/GETTY IMAGES GLP Forum addresses topics of interest associated with good laboratory practices.
More informationSpeakers Title & Biography
Speakers Title & Biography Dr. Janice M. Soreth Deputy Director, FDA Europe Office/CDER, Liaison to EMA Dr. Soreth 20-year agency veteran with unparalleled experience, including serving as CDER's director
More informationStability Studies for Pharmaceutical Products (API and finished products)
A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry Stability Studies for Pharmaceutical Products (API and finished products)
More informationHarmonizing Standards and Specifications
WASHINGTON REPORT Harmonizing Standards and Specifications Jill Wechsler Manufacturers seek more FDA guidance about establishing product specifications during drug development as part of the agency s efforts
More informationProject Management for Human Resources
Project Management for Human Resources *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! HR Managers are asked to juggle a wide variety of assignments and add on special ones as needed.
More informationThreshold of Toxicological Concern Initiatives for Medical Devices Richard Hutchinson, DVM, PhD, DABT J&J Global Surgery Group.
Threshold of Toxicological Concern Initiatives for Medical Devices Richard Hutchinson, DVM, PhD, DABT J&J Global Surgery Group Abstract The Threshold of Toxicological Concern (TTC) is a concept used to
More informationFrom Conversation to Conservation
6 TH ANNUAL CONNECTICUT FOREST CONSERVATION AND RESEARCH FORUM COOPERATIVE EXTENSION SYSTEM College of Agriculture and Natural Resources SOCIETY OF AMERICAN FORESTERS 1900 November 23, 2010 UNIVERSITY
More information2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast
2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As
More informationExperiences with the adoption of the PQRI best practice guidelines when applied to development of an E&L development package for a DPI
Experiences with the adoption of the PQRI best practice guidelines when applied to development of an E&L development package for a DPI March 2011 Anatomy of this presentation A personal list of highlights
More information2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast
2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As
More information2 Day Seminar. Supplier Management for Medical Device Manufacturers 12 RAPS CREDITS. Jun Boston
2 Day Seminar Supplier Management for Medical Device Manufacturers 12 RAPS CREDITS Jun 01 02 Boston Seminar One Registration $ 993 Special Group Discount Register for Four attendees $ 3495 COURSE SUMMARY
More informationIntroduction to Drug Design and Discovery
Introduction to Drug Design and Discovery Course: Drug Design Course code: 0510412 Dr. Balakumar Chandrasekaran Dr. Bilal Al-Jaidi Assistant Professors, Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy,
More informationIssues in Cancer Drug Development of the Future. Janet Woodcock M.D. Deputy Commissioner/Chief Medical Officer, FDA October 5, 2007
Issues in Cancer Drug Development of the Future Janet Woodcock M.D. Deputy Commissioner/Chief Medical Officer, FDA October 5, 2007 Agenda: Scientific Issues n Why improve the quality of cancer clinical
More informationof the TTC Douglas J Ball, MS, DABT
Pharmaceutical Applications of the TTC Douglas J Ball, MS, DABT Agenda Derivation of the TTC Cramer Classification Application of the TTC ICH M7 Leachable and Extractable (L&E) Qualification Case studies
More informationOMICS International Conferences
About OMICS Group OMICS Group is an amalgamation of Open Access Publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of making the information
More informationMAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT
MAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT PharmaSUG Single Day Event Using Standards, Even for Non-Standard
More informationPQRI Research Project Proposal: Reporting and Qualification Thresholds for Leachables in Parenteral and Ophthalmic Drug Products
PQRI Research Project Proposal: Reporting and Qualification Thresholds for Leachables in Parenteral and Ophthalmic Drug Products Prepared by: Doug Ball (Pfizer), Diane Paskiet (West-Monarch), Daniel L.
More informationDeveloping a Phase-Appropriate Extractables and Leachables Program
LIFE SCIENCES HOW DO YOU PERFORM A SUCCESSFUL ILV? HOW DO YOU UNDERSTAND THE CAUSE OF A PAINT FAILURE? HOW DO YOU MEET GLOBAL REGULATORY REQUIREME U DETERMINE THE CAUSE OF LANDING GEAR FAILURE? HOW DO
More informationQuality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical
More informationAgreed with W. Cornell Graduate Program and Tri-I
Drug Development Course From Molecule to Prescription Weill Cornell Graduate School - Tri-Institutional Therapeutics Discovery Institute ABOUT THIS COURSE This course has been designed in collaboration
More informationDRUG SAFETY EVALUATION
DRUG SAFETY EVALUATION DRUG SAFETY EVALUATION SHAYNE C. GAD A John Wiley & Sons, Inc., Publication This book is printed on acid-free paper. Copyright # 2002 by John Wiley and Sons, Inc., New York. All
More informationSan Antonio Bay Partnership
June 27, 2017 9:00 am - 5:00 pm June 28, 2017 9:00 am - 12:45 pm The Needs Your Help! Established in 2010, the (SABP) is a regional, stakeholder-driven planning and management program that is focused on
More informationIs a Career in the. Pharmaceutical. Check out our online Student Center to find out more:
Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aaps.org/forstudents How Do I Know If a Career in the Pharmaceutical Sciences is Right
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationBiocompatibility Testing and Evaluations for Medical Devices
Informa Life Sciences 7th Annual Biocompatibility Testing and Evaluations for Medical Devices 8-9 December 2015 Radisson Blu Royal Hotel, Dublin, Ireland Latest ISO 10993 updates and practical industry
More informationExpanded Access and the Individual Patient IND
Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office
More informationIntroduction to CMC Regulatory Affairs
Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4
More informationRisk Assessments for Host Cell Protein Control Strategies: CDER Experiences
Risk Assessments for Host Cell Protein Control Strategies: CDER Experiences Laurie Graham FDA/CDER Office of Pharmaceutical Quality (OPQ) Office of Policy for Pharmaceutical Quality (OPPQ) 1 Disclaimer
More informationA Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy
A Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy Nicholas Cappuccino, PhD Vice-President, Head of Quality and Scientific Affairs Dr. Reddy s Laboratories,
More information3M Drug Delivery Systems. April 26, 2011
3M MDI Manufacturing April 26, 2011 3M Drug Delivery Systems Drug Delivery Systems Overview 3M Drug Delivery Systems is a division of 3M that is dedicated to the development and manufacturing of inhalation
More information2. Risk-based compliance was also a key component in the FDA's new approach for dealing with electronic records and signatures: 21 CFR Part 11.
LITERATURE REVIEW: Risk management is well known and practiced in many industries and several industry task forces have developed guidance documents that facilitate risk management. Risk management for
More informationManaging QbD From A CMO Perspective
Managing QbD From A CMO Perspective By Cathy Yarbrough The concepts and methods of Quality by Design (QbD), which the automobile, airline, and electronics industries have utilized to enhance the quality
More informationExtractables, Leachables, & Elemental Impurities 2018 West Coast
Extractables, Leachables, & Elemental Impurities 2018 West Coast Ensuring Quality, Safety, and Regulatory Compliance for Drugs & Biologics November 13 14, 2018, Sheraton La Jolla, CA Featuring Lessons
More informationTeeramanas Tanaekakarapong, a peritoneal dialysis patient
Teeramanas Tanaekakarapong, a peritoneal dialysis patient Application of ICHQ9 Risk Management Principles to Assess the Risk of Leachables Adversely Impacting the Quality and/or Safety of Complex Biopharmaceuticals
More information3M Purification Inc. Technical and Scientific Services Global Support for the Life Science Industry. Global Expertise delivered locally
3M Purification Inc. Technical and Scientific Services Global Support for the Life Science Industry Global Expertise delivered locally Global expertise delivered locally As a global leader in measuring,
More informationBiocompatibility evaluation of breathing gas pathways in healthcare applications. Part 1: Evaluation and testing within a risk management process
Provläsningsexemplar / Preview INTERNATIONAL STANDARD ISO 18562-1 First edition 2017-03 Biocompatibility evaluation of breathing gas pathways in healthcare applications Part 1: Evaluation and testing within
More informationNew Drug Product Impurities
Title Page Image - with courtesy of the FDA CDER original web site at www. cder.fda.gov/ New Drug Product Impurities IAGIM Scientific Committee Block JD; Holmann E ; West P NEW DRAFT GUIDANCE FDA Viewpoint
More informationDisinfectant Qualification and Cleanroom Disinfection A Step by Step Workshop
Microrite, Inc. brings you this unique advanced course in ; part of Microrite s Step by Step Workshop Series Participate in the only workshop which will guide you through the process of choosing a cost
More informationNINDS/HEAL Biomarker Programs New Biomarker Initiatives at NIH: Neurological Disorders and Pain
NINDS/HEAL Biomarker Programs New Biomarker Initiatives at NIH: Neurological Disorders and Pain OCTOBER 30, 2018 Mary Ann Pelleymounter, PhD Program Director mary.pelleymounter@nih.gov 1 About the Speaker
More informationDealing with Extractables & Leachables from a Regulatory Perspective - Design of Extractables & Leachables Studies - Safety Assessment of Leachables
Dealing with Extractables & Leachables from a Regulatory Perspective - Design of Extractables & Leachables Studies - Safety Assessment of Leachables Timothy W. Robison, Ph.D., D.A.B.T. Division of Pulmonary,
More informationWhy Does a Project Need a Project Manager and a Business Analyst? 1 Powered by POeT Solvers Limited
Why Does a Project Need a Project Manager and a Business Analyst? 1 www.pmtutor.org Powered by POeT Solvers Limited Agenda What Is A Business Analyst? Why Does A Project Need A Project Manager And A Business
More informationEBC Series with MassDEP Regional Leadership Commissioner Suuberg and the Northeast Region Leadership Team Hot Issues & Ongoing Challenges
EBC Series with MassDEP Regional Leadership Commissioner Suuberg and the Northeast Region Leadership Team Hot Issues & Ongoing Challenges Wednesday, October 24, 2018 McLane Middleton Woburn, Massachusetts
More informationEFFECTIVE CLINICAL TRIALS. NUSAGE PharmEng. Pharmaceutical and Biotechnology Training Program. Copyright 2014 NUSAGE-PharmEng.
EFFECTIVE CLINICAL TRIALS NUSAGE PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry EFFECTIVE CLINICAL TRIALS Objective The intent
More informationStrategic Outsourcing for Success
Strategic Outsourcing for Success Improving Speed to Clinic using External Sourcing Massachusetts Biotechnology Council Meeting November 16, 2012 Cambridge, MA BioProcess Technology Consultants www.bptc.com
More informationOutsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing
Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing By Impact Analytical Introduction About Impact Analytical Impact Analytical is a contract analytical testing
More informationToxic Pollution from Powerplants: Large Emissions, Little Risk
Harvard Center for Risk Analysis APRIL 1999 Volume 7 Issue 2 Risk in Perspective Toxic Pollution from Powerplants: Large Emissions, Little Risk George M. Gray, Ph.D. Although this industry will report
More informationAmerican Association of Pharmaceutical Scientists (AAPS)
American Association of Pharmaceutical Scientists (AAPS) AAPS, King Street, Alexandria, VA, USA* he American Association of Pharmaceu- Scientists (AAPS), founded in 1986, Ttical is an individual membership
More informationPrecision. Proficiency. Proximity.
Precision. Proficiency. Proximity. Precision Accuracy in testing is paramount to ensuring product safety and efficacy. And fast turnaround times are critical to keeping your project on schedule. With
More informationAnalytical Methods Development and Validation
Understanding and Implementing Efficient Analytical Methods Development and Validation Jay Breaux, Kevin Jones, and Pierre Boulas Analytical methods development and validation play important roles in the
More informationKey multiplicity concepts and principles addressed in the Draft Guidance: Multiple Endpoints in Clinical Trials
Key multiplicity concepts and principles addressed in the Draft Guidance: Multiple Endpoints in Clinical Trials Mohammad F. Huque, Ph.D. Office of Biostatistics OTS, CDER/FDA DIA Annual Meeting, Boston,
More informationGPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives
GPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives Stephen Miller, Ph.D. CMC-Lead; Office of New Drug Products Office of Pharmaceutical Quality
More informationAcceptable Intake (AI) and Permitted Daily Exposure (PDE) Data Sharing Project for Pharmaceutical Impurities
Acceptable Intake (AI) and Permitted Daily Exposure (PDE) Data Sharing Project for Pharmaceutical Impurities Dr. William Drewe Business Development Manager David Wilkinson Senior Data Scientist Agenda
More informationCHANGE CONTROL MANAGEMENT FOR A STABILITY PROGRAM
Potential Changes and Minimizing the Impact of Registration CHANGE CONTROL MANAGEMENT FOR A STABILITY PROGRAM Kim Huynh Ba Eecutive Director PHARMALYTIK www.pharmalytik.com Biography Kim Huynh Ba has over
More informationCurrent practices on metabolite profiling and quantification in Drug Development at Boehringer-Ingelheim
Current practices on metabolite profiling and quantification in Drug Development at Boehringer-Ingelheim S Blech EBF Focus Workshop: Metabolite Profiling and Quantification Strategies in Drug R&D Sep 25,
More informationReference Standards for Monoclonal Antibodies: Key Challenges Addressed
CASSS WCBP 2012: 16th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products January 23-25, 2012 Reference Standards for Monoclonal Antibodies: Key Challenges
More informationWELCOME TO THE SCOND ANNUAL: 2016 Waters Corporation 1
WELCOME TO THE SCOND ANNUAL: 2016 Waters Corporation 1 Identification and Quantification of Unwanted Substances in Contact Materials WELCOME 2016 Waters Corporation 2 INTRODUCTION Your Hosts Latest developments
More informationLAB EXPERTS AT YOUR SIDE Over twenty years of experience
LAB EXPERTS AT YOUR SIDE Over twenty years of experience About us SYNLAB Pharma offers a broad range of laboratory services to the biotechnology, pharmaceutical and cosmetic industries as well as to manufacturers
More informationAbout Clinical Trials: What They Can Mean For You?
About Clinical Trials: What They Can Mean For You? Karl Cremer, PharmD and AnnKatrin Petersen, MD, MS January 25, 2012 ClinicalStudy.org Owned and operated by PRI, Inc. 5927 Balfour Court, Suite 201 Carlsbad,
More informationA PMP Among PhDs: Applying Program Management to Biotechnology Research and Commercialization Speaker: Jill Almaguer, PE, MBA, PMP Company: Texas
A PMP Among PhDs: Applying Program Management to Biotechnology Research and Commercialization Speaker: Jill Almaguer, PE, MBA, PMP Company: Texas Heart Institute Website: www.texasheart.org, www.ccobtexas.org
More informationDocumentation requirements for an initial consultation
Language : French or English Documentation requirements for an initial consultation Because of the wide range of medical devices which incorporate, as an integral part, an ancillary medicinal substance,
More informationCMC Considerations for 505(b)(2) Applications. Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C.
CMC Considerations for 505(b)(2) Applications Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C. October 2011 1 Introduction Outline Brief overview of FDA drug approval pathways
More informationPHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
More informationScientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More information2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast
2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As
More information